J

Johnson & Johnson

Makes prescription drugs and medical devices

Principal Scientist - Scientific Workflows & Agentic Cheminformatics

Full-Time
$117k - $201.3k+ Annual performance bonus
Expert
PhD
Cambridge, MA, USA+1 moreMore locations: Spring House, PA, USA
HybridSome travel may be required, including domestic and international travel up to 10%.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A PhD or equivalent substantial experience in cheminformatics, computational chemistry, medicinal chemistry, chemical biology, or a related discipline, with recognized depth of scientific expertise relevant to drug discovery.
  • Deep understanding of compound design, predictive models, and discovery decision-making, with the ability to connect scientific needs and opportunities across disciplines or programs.
  • Strong Python programming skills and experience developing automated workflows, pipelines, or scientific applications to explore scientific questions and create practical proof-of-concept solutions.
  • Familiarity with workflow orchestration and sound software development practices, including version control, testing, and continuous integration and delivery.
  • Hands-on experience using AI-assisted development approaches to build reliable scientific software or automated workflows, with practical experience applying large language models and designing effective interactions between models, tools, and human experts.
  • Demonstrated ability to define scientific direction in ambiguous areas, translate emerging needs into a coherent capability agenda, and influence stakeholders across scientific, data science, and technology organizations.
  • Track record of scientific leadership, cross-disciplinary collaboration, and translating promising ideas into approaches that influence discovery strategy and outcomes beyond a single project.
  • Ability to mentor scientists and engineers, raise scientific and technical standards, and build alignment and capability across a matrixed organization.
  • Ability to travel domestically and internationally up to 10% of the time.
Responsibilities
  • Build trusted partnerships with medicinal chemists, CADD scientists, biologists, DMPK scientists, data scientists, and scientific leaders to understand decision workflows and identify opportunities with impact across projects or discovery areas.
  • Shape and prioritize a portfolio of scientific questions and decision points where agentic approaches can bring together data, models, and expert knowledge to improve the quality or speed of discovery.
  • Define robust and reusable approaches for translating complex scientific questions into workflows that make evidence, assumptions, decisions, and points requiring expert judgment explicit.
  • Design scientifically meaningful use cases, reference datasets, and success criteria that enable rigorous evaluation.
  • Evaluate agent behavior and outputs for scientific validity, reproducibility, uncertainty, appropriate tool use, robustness across scenarios, and relevance to discovery decisions.
  • Capture the scientific insights gained from early applications and use them to define which approaches merit further development and broader adoption.
  • Develop and test agentic prototypes in realistic discovery settings, combining scientific expertise with relevant data, predictive models, computational or laboratory methods, and tools that agents can select and coordinate to address a scientific objective.
  • Provide scientific and technical leadership across a portfolio of agentic prototypes, set priorities and success measures, guide trade-off decisions, and ensure that the work addresses meaningful discovery needs and delivers measurable value.
  • Drive broader adoption of agentic capabilities by integrating them into familiar scientific environments, establishing effective patterns for human–agent collaboration, and building communities of practice across discovery functions.
  • Lead the scientific design, prototyping, and validation of agent-enabled discovery workflows, and partner with data science and platform engineering teams from an early stage on the underlying AI architecture, production implementation, security, and sustained operation. Translate scientific requirements and evidence into reusable capabilities that align with shared architectures and can be deployed across discovery programs.
Desired Qualifications
  • Experience designing and evaluating end-to-end agent-enabled scientific workflows or multi-agent solutions.
  • Strong knowledge of and hands-on experience with public and commercial bioactivity and chemogenomics databases.
  • Demonstrated track record of partnering with platform engineering teams to develop production-ready solutions.

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.

CNBC
Oct 13th, 2026
J&J beats estimates and lifts forecast to $101.2B, but Middle East conflict hurts device sales

Johnson & Johnson (J&J) beat earnings estimates, but the Middle East conflict hurt its medical-device sales in the region. Chief financial officer Joe Wolk said Gulf states such as Kuwait, the UAE, and Saudi Arabia are shifting budgets towards defence. The conflict has not yet raised J&J's costs. Tremfya sales rose 68% to $2.4 billion, beating estimates of about $2.19 billion. Stelara sales, which face generic competition, fell 54% to $716 million, above expectations of $591 million. Darzalex sales rose about 16% to $4.24 billion, short of the $4.4 billion expected. J&J raised its full-year sales forecast to about $101.2 billion at the midpoint, from $101.1 billion. Its adjusted earnings midpoint rose to $11.10 per share from $11.04. Shares closed at $263.73 on Monday, up 27% this year.